Epilepsy Drugmaker's Statements Insulated From Stock Suit

By P.J. D'Annunzio · March 12, 2026, 5:10 PM EDT

A Pennsylvania federal judge has trimmed a shareholder class action against Marinus Pharmaceuticals alleging it misled investors about the probability of success of an epilepsy drug, ruling that certain statements made...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Decision

Case Information

Case Title

BISHINS v. MARINUS PHARMACEUTICALS, INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

June 05, 2024

Recent Articles By P.J.

March 11, 2026
Pa. Justices Hint 3rd Jury Should Decide Misdiagnosis Case
March 11, 2026
Aetna Will Pay $117.7M To Resolve False Billing Suit
February 26, 2026
Health Plans Lack Expert In Avandia MDL, 3rd Circ. Told
February 25, 2026
Philly Says PBMs Can't Exit Suit Over Opioid Crisis
February 24, 2026
Philips Unit Escapes CPAP Machine Whistleblower Case
February 23, 2026
Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit
February 18, 2026
Meta Pixel Tracking Suit Tossed Over Lack Of Standing
February 13, 2026
Olympus Slips Whistleblower Suit Over Testing Practices
February 13, 2026
J&J Hit With $250K Verdict In 2nd Philly Talc Trial
February 10, 2026
Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps